Ruxolitinib as Salvage Therapy in Steroid Refractory Acute Graft Versus Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients

Highlights • Ruxolitinib has a 45% overall response rate as salvage therapy in children with steroid- refractory acute graft versus host disease • Ruxolitinib is associated with significant but reversible adverse effects such as cytopenias and transaminitis

Saved in:
Bibliographic Details
Published inBiology of blood and marrow transplantation Vol. 23; no. 7; pp. 1122 - 1127
Main Authors Khandelwal, Pooja, MD, Teusink-Cross, Ashley, PharmD, Nelson, Adam S, MD, Dandoy, Christopher E, MD, El-Bietar, Javier, MD, Marsh, Rebecca A, MD, Kumar, Ashish R, MD, PhD, Grimley, Michael S, MD, Davies, Stella M, MBBS, PhD, Jodele, Sonata, MD, Myers, Kasiani C, MD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2017
Subjects
Hematology, Oncology and Palliative Medicine
Jak inhibitor
Ruxolitinib
SR graft-versus-host disease
SR-GVHD in children
ruxolitinib
Jak inhibitor
SR graft versus host disease
SR-GVHD in children
Ruxolitinib
SR graft-versus-host disease
Online AccessGet full text

Cover

More Information
Summary:Highlights • Ruxolitinib has a 45% overall response rate as salvage therapy in children with steroid- refractory acute graft versus host disease • Ruxolitinib is associated with significant but reversible adverse effects such as cytopenias and transaminitis
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2017.03.029